{
    "Trade/Device Name(s)": [
        "DRI Cocaine Metabolite Assay",
        "Alinity c Cocaine Assay"
    ],
    "Submitter Information": "Microgenics Corporation",
    "510(k) Number": "K211973",
    "Predicate Device Reference 510(k) Number(s)": [
        "K181499"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIO"
    ],
    "Summary Letter Date": "June 22, 2021",
    "Summary Letter Received Date": "June 25, 2021",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.3250"
    ],
    "Regulation Name(s)": [
        "Cocaine and cocaine metabolite test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Benzoylecgonine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        "Alinity c analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay"
    ],
    "Methodologies": [
        "Homogeneous enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for DRI Cocaine Metabolite Assay for qualitative and semi-quantitative determination of benzoylecgonine in urine on the Alinity c analyzer",
    "Indications for Use Summary": "Homogeneous enzyme immunoassay for qualitative and/or semi-quantitative determination of benzoylecgonine (cocaine metabolite) in human urine at cutoff concentrations of 150 ng/mL or 300 ng/mL on the Alinity c analyzer; for specimen dilution prior to confirmatory testing or quality control procedures; preliminary test for in vitro diagnostic use only.",
    "fda_folder": "Toxicology"
}